Burning Rock Biotech (Burning Rock Biotech) EV-to-EBIT : 0.04 (As of May. 31, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Burning Rock Biotech EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Burning Rock Biotech's Enterprise Value is $-3.52 Mil. Burning Rock Biotech's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-81.01 Mil. Therefore, Burning Rock Biotech's EV-to-EBIT for today is 0.04.

The historical rank and industry rank for Burning Rock Biotech's EV-to-EBIT or its related term are showing as below:

BNR' s EV-to-EBIT Range Over the Past 10 Years
Min: -99.99 Med: -1.53 Max: 0.16
Current: 0.08

During the past 7 years, the highest EV-to-EBIT of Burning Rock Biotech was 0.16. The lowest was -99.99. And the median was -1.53.

BNR's EV-to-EBIT is ranked better than
96.04% of 101 companies
in the Medical Diagnostics & Research industry
Industry Median: 21.17 vs BNR: 0.08

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Burning Rock Biotech's Enterprise Value for the quarter that ended in Mar. 2024 was $-2.18 Mil. Burning Rock Biotech's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-81.01 Mil. Burning Rock Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 3,713.57%.

Burning Rock Biotech EV-to-EBIT Historical Data

The historical data trend for Burning Rock Biotech's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Burning Rock Biotech EV-to-EBIT Chart

Burning Rock Biotech Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-33.41

-6.26

-0.77

-0.12

Burning Rock Biotech Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial															-1.37	-1.12	-0.15	-0.12	-

Competitive Comparison of Burning Rock Biotech's EV-to-EBIT

For the Diagnostics & Research subindustry, Burning Rock Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Burning Rock Biotech's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Burning Rock Biotech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Burning Rock Biotech's EV-to-EBIT falls into.

Burning Rock Biotech EV-to-EBIT Calculation

Burning Rock Biotech's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	-3.516	/	-81.008
	=	0.04

Burning Rock Biotech's current Enterprise Value is $-3.52 Mil.
Burning Rock Biotech's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-81.01 Mil.

Burning Rock Biotech (NAS:BNR) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Burning Rock Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	-81.008	/	-2.1814053
	=	3,713.57 %

Burning Rock Biotech's Enterprise Value for the quarter that ended in Mar. 2024 was $-2.18 Mil.
Burning Rock Biotech's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-81.01 Mil.

Burning Rock Biotech EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Burning Rock Biotech's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Burning Rock Biotech (Burning Rock Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Burning Rock Biotech Ltd (NAS:BNR) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

BNR:UK 6BUA:Germany

Address

No. 5, Xingdao Ring Road North, International Bio Island, Guangzhou, CHN, 510005

Website

https://www.brbiotech.com

Burning Rock Biotech Ltd is a cancer diagnostics company. Its products include OncoScreen Plus and ColonCore. The company has developed various cancer detection products, involving tumor targeting, differentiation of benign and malignant tumors, monitoring of small residual lesions, prediction of tumor recurrence progress, and detection of tumor sensitivity. It offers 12 NGS-based cancer therapy selection tests comprising a broad range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer, using both tissue and liquid biopsy samples.